🇺🇸 FDA
Pipeline program

Ruxolitinib

ZJU-HSCT-BOS

Phase 2 small_molecule active

Quick answer

Ruxolitinib for Bronchiolitis Obliterans Syndrome is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Bronchiolitis Obliterans Syndrome
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials